Executive Summary

Oct 2019
PROSPECTS
Stable but undynamic performance for dermatologicals

Dermatologicals recorded stable but undynamic current value growth in 2019, with larger categories such as antipruritics recording a weak performance. Smaller product areas of topical antifungals and hair loss treatments however, continued to experience more stable demand, supported by heavy marketing in Finland by major players.

Tentative recovery for vaginal antifungals with

Despite recording declining sales in 2019, vaginal antifungals is beginning to experience a tentative recovery as many Finns suffer from yeast infections. Rather than visiting a doctor, they are showing an increasing preference for self-care in this matter, which they can address in the privacy of their own homes.

Increasing presence of private label in cold sore treatments may restrain stronger value growth recovery

Cold sore treatments also experienced a tentative recovery in 2019 in current value terms, although it recorded ongoing stagnant demand. Higher value growth is being supported by innovative products with Zoviduo from GSK Consumer Healthcare, which has the dual effect of stopping the growth of the herpes virus in addition to reducing inflammation and redness, continuing to gain share and record strong current value growth.

COMPETITIVE LANDSCAPE
Leading players continue to lose share to generics

Dermatologicals continued to be led by large players Orion Oyj, Janssen-Cilag Oy and Bayer Oy in 2019, although all three continued to lose share to smaller players and generics producers such as Orifarm Oy and Paranova Oy, which both recorded strong performances in topical antifungals, vaginal antifungals and antipruritics. However, Orion’s brand Hydrocortison retained its lead of antipruritics in 2019, where it faced increasing pressure from Hydrocortison Ratiopharm, which continued to gain ground, and competition from another Orion brand Pantyson.

Ratiopharm launches new vaginal antifungals line

The consolidated competitive landscape of vaginal antifungals is likely to experience some disruption over the forecast period, with dynamic player Ratiopharm entering the category towards the end of the review period with a series of products (Vagibalance ratiopharm and Vagimoist ratiopharm) and targeting women suffering from yeast infections or dryness due to a number of factors. The player is likely to appeal to more price-conscious consumers due to its lower price point.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Dermatologicals in Finland

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Medicated Skin Care industry in Finland with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Medicated Skin Care industry in Finland, our research will save you time and money while empowering you to make informed, profitable decisions.

The Medicated Skin Care in Finland market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Medicated Skin Care in Finland?
  • What are the major brands in Finland?
  • What are the most popular formats for acne treatments?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Dermatologicals in Finland - Category analysis

HEADLINES

PROSPECTS

Stable but undynamic performance for dermatologicals
Tentative recovery for vaginal antifungals with
Increasing presence of private label in cold sore treatments may restrain stronger value growth recovery

COMPETITIVE LANDSCAPE

Leading players continue to lose share to generics
Ratiopharm launches new vaginal antifungals line

CATEGORY DATA

Table 1 Sales of Dermatologicals by Category: Value 2014-2019
Table 2 Sales of Dermatologicals by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Dermatologicals: % Value 2015-2019
Table 4 LBN Brand Shares of Dermatologicals: % Value 2016-2019
Table 5 LBN Brand Shares of Hair Loss Treatments: % Value 2016-2019
Table 6 Forecast Sales of Dermatologicals by Category: Value 2019-2024
Table 7 Forecast Sales of Dermatologicals by Category: % Value Growth 2019-2024

Consumer Health in Finland - Industry Overview

EXECUTIVE SUMMARY

Stable demand for consumer health as consumers increasingly look to self-care and prevention
Ongoing debate over restrictive OTC environment could lead to opening up of distribution
Orion holds fragile lead over fragmented consumer health, while GSK Consumer Healthcare vastly improves share through Pfizer deal
Modern grocery retailers and internet retailing continue to gain share from leading distribution channel chemists/pharmacies
Positive performance for consumer health despite a not so optimistic economic outlook

MARKET INDICATORS

Table 8 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 9 Life Expectancy at Birth 2014-2019

MARKET DATA

Table 10 Sales of Consumer Health by Category: Value 2014-2019
Table 11 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 12 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 13 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 14 Penetration of Private Label in Consumer Health by Category: % Value 2014-2019
Table 15 Distribution of Consumer Health by Format: % Value 2014-2019
Table 16 Distribution of Consumer Health by Format and Category: % Value 2019
Table 17 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 18 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024

APPENDIX

OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine

SWITCHES

DEFINITIONS

SOURCES

Summary 1 Research Sources